Study aims to Fine-Tune antibiotic dosing for ICU patients

NCT ID NCT07681544

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study looks at how the antibiotic meropenem behaves in the blood of critically ill adults in the intensive care unit. Researchers compare different doses (1 gram vs. 2 grams) and infusion times (30 minutes vs. 3 hours) to see which keeps drug levels above the needed threshold longer. Participants receive meropenem as part of standard care and provide blood samples during the first 48 hours. The goal is to help doctors choose the best dosing strategy for treating infections before the exact bacteria are known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

meropenem

What this could lead to

If successful, this study could help doctors choose the best meropenem dose and infusion method for critically ill patients, potentially improving infection treatment.

What could go wrong

This is a small observational study with only 26 participants, so results may not apply to all patients. It does not test a new drug or directly measure patient outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRITICALLY ILL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina